This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
2 Intriguing Medical Stocks to Buy for Steady Growth as Earnings Approach
by Shaun Pruitt
Among the medical sector, Alcon (ALC) and Prestige Consumer Healthcare (PBH) are two intriguing stocks to buy for growth as their quarterly results approach on Tuesday, May 14.
BioLife Solutions, Inc. (BLFS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioLife Solutions (BLFS) delivered earnings and revenue surprises of 26.92% and 8.28%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Unveiling Prestige Consumer Healthcare (PBH) Q4 Outlook: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Prestige Consumer Healthcare (PBH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
Will Cresco Labs Inc. (CRLBF) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Cresco Labs Inc. (CRLBF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IM Cannabis Corp. (IMCC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
IM Cannabis (IMCC) delivered earnings and revenue surprises of 0% and 14.14%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
PBH vs. ABT: Which Stock Is the Better Value Option?
by Zacks Equity Research
PBH vs. ABT: Which Stock Is the Better Value Option?
Prestige Consumer Healthcare (PBH) Earnings Expected to Grow: What to Know Ahead of Q4 Release
by Zacks Equity Research
Prestige Consumer Healthcare (PBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain Prestige Consumer (PBH) Stock Now
by Zacks Equity Research
The robust strength of Prestige Consumer's (PBH) diversified portfolio bodes well for investors.
Here's Why Prestige Consumer Healthcare (PBH) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Prestige Consumer (PBH) Banks on its Portfolio Amid Cost Woes
by Zacks Equity Research
Prestige Consumer (PBH) develops long-term partnerships across its diverse retail footprint and invests heavily in the e-commerce channel.
Here's Why Prestige Consumer Healthcare (PBH) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Medtronic (MDT) Down 2.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Medtronic (MDT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Prestige Consumer Healthcare (PBH) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Reasons to Retain Prestige Consumer (PBH) Stock for Now
by Zacks Equity Research
Investors are optimistic about Prestige Consumer (PBH) on increasing gain in market share for its wide array of brands.
Why Prestige Consumer Healthcare (PBH) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
BellRing Brands Inc. (BRBR) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
BellRing Brands (BRBR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Prestige Consumer (PBH) Q3 Earnings Top, Gross Margin Expands
by Zacks Equity Research
Prestige Consumer's (PBH) third-quarter fiscal 2024 results reflect the power of a well-positioned and diversified portfolio.
Prestige Consumer Healthcare (PBH) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Prestige Consumer Healthcare (PBH) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Prestige Consumer Healthcare (PBH) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Prestige Consumer Healthcare (PBH) delivered earnings and revenue surprises of 1.92% and 0.89%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
PBH vs. BSX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PBH vs. BSX: Which Stock Is the Better Value Option?
Prestige Consumer Healthcare (PBH) Reports Next Week: What Awaits?
by Zacks Equity Research
Prestige Consumer Healthcare (PBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
High Tide Inc. (HITI) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
High Tide Inc. (HITI) delivered earnings and revenue surprises of 166.67% and 1.07%, respectively, for the quarter ended October 2023. Do the numbers hold clues to what lies ahead for the stock?